The spectrum of chronic lymphocytic leukemia.
The state of differentiation of the lymphocytes in chronic lymphocytic leukemia is a factor that appears to correlate with the presence and severity of clinical manifestations of the disease and with the incidence of complications. Among drug regimens proposed to date, the most efficacious in poorly differentiated disease appear to be the three- and four-drug combinations.
D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000473:pathology*; D008214:Lymphocytes / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone